peginterferon alfa 2b 48kDA (BIP48) / Oswaldo Cruz Foundation - LARVOL DELTA

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. (PubMed, BMC Pharmacol Toxicol) - P1; "BIP48 showed the expected pharmacokinetic profile for a pegylated product with a branched molecular structure. Compared to PEGASYS®, the magnitude absorption was similar, but time parameters were consistent with slower elimination. Further studies should be conducted to evaluate the clinical implications of these findings. A phase II-III repeated-dose clinical trial is ongoing to study these findings in patients with chronic hepatitis C virus infection."

Clinical • Journal • PK/PD data • Biosimilar • Hepatitis C Virus • Immunology • Infectious Disease